The global business of the pharmaceutical industries is gigantic. In 2018 alone, the ten most important pharmaceutical companies in the world generated sales of around 400 billion euros (around 40% of the global market share). The volume of the entire world pharmaceutical market has an estimated value of around 900 billion euros and is estimated to reach 1,500 billion by 2022. Western Europe alone represents 20% of this market, while North America 37% (2018). In this complex scenario, quality products obtained with innovative and above all green technologies find more and more space. Understanding the needs of this market, our products can be easily inserted and widely used. The quality is attested by the production chain and is attested by the quality and strict rules of the HACCP, in addition the company is gearing up to implement the European regulations regarding GMP.

To quote an example of an interest molecule, we can talk about Lycopene. This tetraterpene is a molecule having an important antioxidant activity, thanks to the abundance of conjugated double bonds, which can easily inactivate oxidizing radical species. Lycopene is found in abundance in all fruits characterized by red color, and mainly in tomatoes. Thanks to collaborations with various Italian and foreign companies, Exenia Group srl, has developed an extraction of this molecule from some waste from the tomato production chain, thus obtaining a quality product, without any trace of solvent. The final product was an oil enriched in lycopene, useful for the pharmaceutical formulation of anti-aging creams. In addition, through micronization, this compound has been converted into a powder, more easily permeable to the skin and more bioavailable at the gastrointestinal level.

Through this technology it is possible to re-evaluate food industry waste, obtaining extracts with high added value, in a market that increasingly emphasizes the importance of good production practices, the circular economy and green chemistry. With the further step of micronization, the added value of the products is further increased, making them ready to be processed in GMP by the pharmaceutical industries.

In this and many other cases, the company has demonstrated that it possesses technology and skills to arrive at the design / production of products or intermediates with high added value, very close to the final formulation. In this way they can be used as they are, or included in final productions for food, nutraceutical, pharmaceutical, cosmetic and cosmeceutical sectors.